Trials / Completed
CompletedNCT00452725
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 3 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAXOMAT ®, biosynthetic growth hormone | 2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration |
Timeline
- Start date
- 1997-10-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2007-03-27
- Last updated
- 2010-10-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00452725. Inclusion in this directory is not an endorsement.